Abstract The United States Food and Drug Administration (US FDA) has always been a
forerunner in drug evaluation and supervision. Over the past 31 years, 1050 drugs …

Gastrointestinal stromal tumours (GIST) have an incidence of~ 1.2 per 105 individuals per
year in most countries. Around 80% of GIST have varying molecular changes, predominantly …

1 ESGE recommends endoscopic ultrasonography (EUS) as the best tool to characterize
subepithelial lesion (SEL) features (size, location, originating layer, echogenicity, shape) …

There has been huge progress in the discovery of targeted cancer therapies in recent years.
However, even for the most successful and impactful cancer drugs which have been …

Owing to the dysregulation of protein kinase activity in many diseases including cancer, the
protein kinase enzyme family has become one of the most important drug targets in the 21st …

When gastrointestinal stromal tumour (GIST), the most common form of sarcoma, was first
recognized as a distinct pathological entity in the 1990s, patients with advanced-stage …

In the past two decades, several molecular targeted inhibitors have been developed and
evaluated clinically to improve the survival of patients with cancer. Molecular targeted …

Gastric cancer is a heterogeneous cancer, making treatment responses difficult to predict.
Here we show that we identify two distinct molecular subtypes, mesenchymal phenotype …

Summary Ripretinib (DCC-2618) was designed to inhibit the full spectrum of mutant KIT and
PDGFRA kinases found in cancers and myeloproliferative neoplasms, particularly in …

Background Until now, only imatinib and sunitinib have proven clinical benefit in patients
with gastrointestinal stromal tumours (GIST), but almost all metastatic GIST eventually …